+44 7868 792050
John M Baust
CPSI Biotech, USA
Posters & Accepted Abstracts: Pancreat Disord Ther
There is a pressing need for the development of new devices facilitating advanced minimally invasive approaches for the in situ treatment of pancreatic cancer (PaCa). Additionally, studies now suggest that combinatorial approaches may provide for personalization of strategies to treat PaCa. While promising the development of personalized, minimally invasive, combinatorial therapies has been slowed as a result of technological limitations. To this end, we have developed an endoscopic ultrasound (EUS) compatible cryo catheter (FrostBite) designed for the transesophageal in situ ablation of PaCa. FrostBite has a 13cm long 17 gauge needle with a 3cm ablation tip attached to a ~1m flexible catheter to enable passage through the working channel of a EUS endoscope. Studies have demonstrated the generation of a 3.0 cm diameter iceball with a tip temperature of â�?¤170�?ºC and penetration of the -40 and -20�?ºC isotherms to 2 cm and 2.5 cm, respectively following a 5 min freeze. Analysis of tissue destruction using tissue engineered PaCa tumor revealed a >2.5 cm ablation area 1 day post freeze. Pilot in vivo studies in a porcine model demonstrated the generation of a 2 cm freeze zone within 4 minutes. This presentation will discuss performance testing of the FrostBite EUS-cryo catheter in conjunction with the supercritical nitrogen (SCN) cryoablation system. Additionally, discussion of the impact of adjunctive drug based treatments with freezing to provide for more targeted and personalized treatment paradigm will be included. Together, these studies have demonstrated the potential of this new approach to provide a next-generation strategy for the treatment of PaCa.